is a leading company specialized in the production of high-quality and cost-effective generic Active Pharmaceutical Ingredients (APIs). Our commitment lies in offering a diverse range of APIs across various treatment segments. With a strong focus on research and development, we are continuously expanding our portfolio.
Over the years, Parsian has fostered successful collaborations for the transfer of cutting-edge technologies to synthesize and produce novel APIs and granules in Iran. Our expertise and dedication in this domain enable us to provide reliable solutions to meet the growing demand for affordable and accessible pharmaceutical products.
Some of our competitive advantages are:
- Hardworking, young and scientific team
- Knowledge-base company
- Very high agility and flexibility
- Close connection with research centers
- Priority of quality over price
- Comprehensive customer support
Formulation and Granulation
Synthesis and Analysis of APIs
To be the Best in Quality
Research & Development
Parsian pharmaceutical Co. implements numerous cooperation projects with leading pharmaceutical companies throughout Iran for meeting the domestic pharmaceutical industries need for high-tech active pharmaceutical ingredients (APIs) and granules i.e. General API, Hazardous API and Hazardous granule with cutting-edged technology and high standards, as one of the most evolved industries in Iran.
- Focus on Excellence in APIs Manufacturing
- Leading Market For Anti Diabetic APIs
- Novel Oncology APIs And Granules
- Our Focus On Multiple Sclerosis Pipeline
Our
Article
Amyotrophic lateral sclerosis (ALS)
Review over Amyotrophic Lateral Sclerosis (ALS) and the First FDA-Approved Drug for Treatment of
Comprehending Heart Failure and Its Therapeutic Approaches
Comprehending Heart Failure and Its Therapeutic Approaches Introduction to Heart Failure Heart failure
Breast Cancer Awareness Month
Breast Cancer Awareness October is Breast Cancer Awareness Month, an annually campaign to raise
Dapagliflozin in Patients with Type 2 Diabetes
Benefits of Dapagliflozin When in Patients with Type 2 Diabetes Abstracts Dapagliflozin reduces the
Soft Tissue Sarcoma
Tyrosine kinase inhibitors in Soft Tissue Sarcomas treatment Sarcomas are a group of
Molnupiravir
Molnupiravir may be effective against the omicron sub-variant BA.5 According to a study
Our
Customers